Sage Journals: Discover world-class research

Abstract

Background

Transgender women are a key population in the HIV epidemic globally, including in Peru. This cross-sectional epidemiological study characterized the pre-exposure prophylaxis (PrEP) cascade in adolescent and young adult transgender women in Peru to inform roll-out of early HIV prevention efforts.

Methods

Between February-July 2022, a community-recruited sample of HIV-negative or status unknown young transgender women (n = 140) in Peru completed a socio-behavioral survey and biological testing for HIV and bacterial STIs. Logistic regression models estimated the association of sociodemographic, healthcare, and behavioral factors to PrEP indication and willingness.

Results

Median age was 22 years (range = 16-24 years); 65.7% reported sex work and 28.6% homelessness. Overall, 45.7% had a PrEP indication based on past 6 months HIV behavioral risk profiles. In a multivariable model, sex work (aRR = 2.27; 95% CI = 1.24-4.17) and homelessness (aRR = 1.27; 95% CI = 1.00-1.60) were associated with PrEP indication. More than one-third (38.6%) had never been HIV tested; 25.3% were tested >1 year ago. Only 34.3% heard of daily oral PrEP, 8.6% reported ever PrEP use, and 5.0% current PrEP use. Nearly half (49.3%) reported willingness to take daily oral PrEP. In a multivariable model, younger age was associated with increased willingness to use PrEP (aRR = 0.92; 95% CI = 0.87-0.98). Highest ranked PrEP preferences were a daily oral pill (35.7%), implant (32.1%), and injection by a provider (10.0%).

Conclusions

PrEP indication and willingness were high in this sample, but HIV testing and PrEP uptake were low. Findings highlight opportunities for age-responsive and contextually-relevant interventions to increase HIV prevention among young transgender women in Peru.

Keywords

Transgender adolescent Peru PrEP HIV prevention

Get full access to this article

View all access options for this article.

References

Stutterheim

van Dijk

Wang

, et al. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis. PLoS One 2021; 16(12): e0260063. DOI: 10.1371/journal.pone.0260063.

Silva-Santisteban

Raymond

Salazar

, et al. Understanding the HIV/AIDS epidemic in transgender women of Lima, Peru: results from a sero-epidemiologic study using respondent driven sampling. AIDS Behav 2012; 16(4): 872–881. DOI: 10.1007/s10461-011-0053-5.

Dayton

Fonner

Plourde

, et al.

A scoping review of oral pre-exposure prophylaxis for cisgender and transgender adolescent girls and young women: what works and where do we go from here?

AIDS Behav 2023; 27(10): 3223–3238. DOI: 10.1007/s10461-023-04043-x.

Poteat

Scheim

Xavier

, et al. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr 2016;72 Suppl 3(Suppl 3):S210-s219. doi:10.1097/QAI.0000000000001087.

Suarez

Logie

Arocha

, et al. Contesting everyday violence: Resilience pathways of gay and transgender youth in Peru. Global Publ Health 2021; 16(5): 706–728. DOI: 10.1080/17441692.2020.1856397.

Reisner

Aguayo-Romero

Perez-Brumer

, et al. A life course health development model of HIV vulnerabilities and resiliencies in young transgender women in Peru. Glob Health Res Policy 2023; 8(1): 32. DOI: 10.1186/s41256-023-00317-y.

Naz-McLean

Clark

Reisner

, et al. Decision-making at the intersection of risk and pleasure: a qualitative inquiry with trans women engaged in sex work in Lima, Peru. AIDS Behav 2022; 26(3): 843–852. DOI: 10.1007/s10461-021-03445-z.

Reisner

Perez-Brumer

McLean

, et al. Perceived barriers and facilitators to integrating HIV prevention and treatment with cross-sex hormone therapy for transgender women in Lima, Peru. AIDS Behav 2017; 21(12): 3299–3311. DOI: 10.1007/s10461-017-1768-8.

Carosella

Huerta

Galea

, et al. A cross-sectional analysis of self-reported needs and health service utilization among transgender women in Lima, Peru. LGBT Health 2023; 10(7): 535–543. DOI: 10.1089/lgbt.2022.0054.

10.

Perez-Brumer

Naz-McLean

Huerta

, et al. The wisdom of mistrust: qualitative insights from transgender women who participated in PrEP research in Lima, Peru. J Int AIDS Soc 2021; 24(9): e25769. DOI: 10.1002/jia2.25769.

11.

Konda

Torres

Marino

, et al. Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study. J Int AIDS Soc. 2022;25(Suppl 5):e25974. DOI: 10.1002/jia2.25974.

12.

Moriarty

Segura

Gonzales

, et al. Assessing sexually transmitted infections and HIV risk among transgender women in Lima, Peru: beyond behavior. LGBT Health 2019; 6(7): 370–376. DOI: 10.1089/lgbt.2018.0087.

13.

Deutsch

Glidden

Sevelius

, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV 2015; 2(12): e512–e519. DOI: 10.1016/S2352-3018(15)00206-4.

14.

Grant

Lama

Anderson

, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587–2599. DOI: 10.1056/NEJMoa1011205.

15.

Ogbuagu

Ruane

Podzamczer

, et al. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double, placebo-controlled, phase 3 trial. Lancet HIV 2021; 8(7): e397–e407. DOI: 10.1016/S2352-3018(21)00071-0.

16.

Landovitz

Donnell

Clement

, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021; 385(7): 595–608. DOI: 10.1056/NEJMoa2101016.

17.

Murphy

Bowra

Adams

, et al. PrEP policy implementation gaps and opportunities in Latin America and the Caribbean: a scoping review. Ther Adv Infect Dis 2023; 10: 20499361231164030. DOI: 10.1177/20499361231164030.

18.

Peru Ministry of Health . Norma Tecnica de Salud “Prevencion Combinada del Virus de La Inmunodeficiencia Humana Para Poblaciones en alto Riesgo; 2023.

19.

Veloso

Caceres

Hoagland

, et al. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study. Lancet HIV 2023; 10(2): e84–e96. DOI: 10.1016/S2352-3018(22)00331-9.

20.

Lama

Brezak

Dobbins

, et al. Design strategy of the sabes study: diagnosis and treatment of early HIV infection among men who have sex with men and transgender women in Lima, Peru, 2013-2017. Am J Epidemiol 2018; 187(8): 1577–1585. DOI: 10.1093/aje/kwy030.

21.

Hidalgo

Petras

Chen

, et al. The gender minority stress and resilience measure: psychometric validity of an adolescent extension. Clin Pract Pediatr Psychol 2019; 7(3): 278–290. DOI: 10.1037/cpp0000297.

22.

Centers for Disease Control and Prevention (CDC) . US public health service: preexposure prophylaxis for the prevention of HIV infection in the United States--2021 update: a clinical practice guideline, https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf (2021).

23.

Zou

. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159(7): 702–709. DOI: 10.1093/aje/kwh090.

24.

Borquez

Guanira

Revill

, et al. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. Lancet Public Health 2019; 4(3): e127–e136. DOI: 10.1016/S2468-2667(18)30236-6.

25.

Yager

Brooks

Brothers

, et al. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate among transgender adolescents and young adults without HIV receiving gender affirming hormones. AIDS Res Hum Retrovir 2022; 38(11): 840–846. DOI: 10.1089/AID.2022.0043.

26.

Yager

Brooks

Brothers

, et al. Gender-affirming hormone pharmacokinetics among adolescent and young adult transgender persons receiving daily emtricitabine/tenofovir disoproxil fumarate. AIDS Res Hum Retrovir 2022; 38(12): 939–943. DOI: 10.1089/AID.2022.0044.

27.

Del Rio-Gonzalez

Lameiras-Fernandez

Modrakovic

, et al. Global scoping review of HIV prevention research with transgender people: transcending from trans-subsumed to trans-centred research. J Int AIDS Soc 2021; 24(9): e25786. DOI: 10.1002/jia2.25786.

28.

Temelkovska

Moriarty

Huerta

, et al. Social networks play a complex role in HIV prevention knowledge, attitudes, practices, and the uptake of PrEP through transgender women communities centered around three “casas trans” in Lima, Peru: a qualitative study. J Int Assoc Phys AIDS Care 2023; 22: 23259582231196705. DOI: 10.1177/23259582231196705.

29.

Clark

Reisner

Perez-Brumer

, et al. TransPrEP: results from the pilot study of a social network-based intervention to support PrEP adherence among transgender women in Lima, Peru. AIDS Behav 2021; 25(6): 1873–1883. DOI: 10.1007/s10461-020-03117-4.

30.

Longino

Montano

Sanchez

, et al.

Increasing PrEP uptake and adherence among MSM and TW sex workers in Lima, Peru: what and whom do different patients trust?

AIDS Care 2020; 32(2): 255–260. DOI: 10.1080/09540121.2019.1634787.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.31 MB

The PrEP cascade in a sample of HIV-negative or unknown status adolescent and young adult transgender women in Peru

Abstract

Background

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material